Non-clear cell renal cell carcinomas (nccRCC) represent a highly heterogeneous group of kidney tumors, consisting of the following subtypes: papillary carcinomas, chromophobe renal cell carcinoma, so-called unclassified carcinomas or aggressive uncommon carcinomas such as Bellini carcinoma, renal cell carcinoma (RCC) with ALK rearrangement or...
-
June 2021 (v1)Journal articleUploaded on: December 4, 2022
-
December 2012 (v1)Journal articleSerum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.
Regarding the frequency of muscular complains with the use of tyrosine kinase inhibitors (TKIs), we hypothesize that creatine kinase (CK) elevation may be more frequent than usually reported. We conducted a prospective study on patients treated with TKIs for solid tumors, to assess the incidence of CK increase on treatment. Most of the patients...
Uploaded on: October 11, 2023 -
December 2012 (v1)Journal articleSerum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.
Regarding the frequency of muscular complains with the use of tyrosine kinase inhibitors (TKIs), we hypothesize that creatine kinase (CK) elevation may be more frequent than usually reported. We conducted a prospective study on patients treated with TKIs for solid tumors, to assess the incidence of CK increase on treatment. Most of the patients...
Uploaded on: December 4, 2022 -
2019 (v1)Journal article
Purpose: Radiation-induced sarcoma (RIS) is a rare but serious event. Its occurrence has been discussed during the implementation of new radiation techniques and justified appropriate radioprotection requirements. New approaches targeting intrinsic radio-sensitivity have been described, such as radiation-induced CD8 T-lymphocyte apoptosis...
Uploaded on: December 4, 2022 -
2016 (v1)Journal article
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, JUN 03-07, 2016
Uploaded on: December 3, 2022 -
November 23, 2018 (v1)Journal article
BACKGROUND: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent...
Uploaded on: March 8, 2024 -
March 2015 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
July 2017 (v1)Journal article
International audience
Uploaded on: February 28, 2023 -
September 2020 (v1)Journal article
No description
Uploaded on: October 17, 2023 -
February 2020 (v1)Journal article
International audience
Uploaded on: December 3, 2022